Parataxis Acquires Bridge Biotherapeutics for Bitcoin Treasury Transformation
Parataxis Holdings acquires Bridge Biotherapeutics, converting it into Parataxis Korea for Bitcoin treasury services.
- Parataxis acquires Bridge Biotherapeutics, Edward Chin joins the board.
- Creating first KOSDAQ-listed Bitcoin treasury platform.
- Bridge Bio continues biotech operations under existing leadership.
Parataxis Holdings has announced the acquisition of South Korea-listed Bridge Biotherapeutics for KRW 25 billion, targeting a transformation into a Bitcoin-native treasury service.
This acquisition illustrates a strategic shift in bridging biotech operations with cryptocurrency treasury services, with immediate influence on Bitcoin exposure in Korean public markets.
Parataxis to Acquire Bridge Biotherapeutics for Bitcoin Treasury Expansion Parataxis Holdings’ move to acquire Bridge Biotherapeutics involves a KRW 25 billion investment. By transforming Bridge Biotherapeutics into Parataxis Korea, the company will pivot towards a Bitcoin-native treasury service. This marks a notable shift for the biotech firm—which will remain listed on KOSDAQ—and opens a new chapter in its operational focus.
Leading the transition, Parataxis Holdings’ CEO Edward Chin will join Bridge Biotherapeutics’ board. Meanwhile, Partner Andrew Kim will assume the role of CEO for the new entity. This restructuring aims to serve Korean institutional demand for Bitcoin.
“We are excited to transition Bridge Biotherapeutics into Parataxis Korea to pioneer a Bitcoin-native treasury service for institutions.” — Edward Chin, Founder and CEO of Parataxis Holdings
Immediate market effects of this transaction center on Bitcoin, as the new company focuses solely on this cryptocurrency as a treasury asset. Traditional market structures in Korea will witness a new player with this unique approach.
The strategic move aligns with global precedents like those of MicroStrategy, but as an unprecedented step in Korea, it signifies a novel route for KOSDAQ-listed entities. No immediate effects on Ethereum or other altcoins have been reported.
Regulatory approval is pending with a Bridge Biotherapeutics shareholder vote set for August 2025. Broader market responses are pinned on this outcome, ensuring institutional and public interest is kept at the forefront. Historical trends suggest financial markets might observe increased institutional BTC activities.
More From Crypto News
X100 Exploit Proceeds Split Into Four 400-ETH Wallets
X100 exploit proceeds have reportedly been divided into four equal destination wallets, each holding 400 ETH, bringing the observed total distributed across the...
Bitcoin Refuses to Break: @jvisserlabs on Market Resilience
Bitcoin is holding where many expected it to crack. Crypto analyst @jvisserlabs flagged the pattern on X, pointing out that Bitcoin’s repeated refusal to break...
Ethereum Exchange Withdrawals Hit Four-Month High: Santiment
Ethereum exchanges recorded a one-day net withdrawal of 169,770 ETH, the largest single-day outflow in more than four months, on-chain analytics firm Santiment...
Bitcoin ETFs See $773M Two-Day Outflows as BTC Tests $80K
Bitcoin spot ETFs recorded a combined $773 million in net outflows across two consecutive trading sessions, coinciding with Bitcoin probing the $80,000 price le...
Initia Halts After Hacker Mints $2.7M in Crypto
A reported exploit on the Initia blockchain has allegedly allowed an attacker to mint approximately $2. 7 million in unauthorized crypto, forcing the network to...
BlackRock Bitcoin ETF Caps Gains to Cushion Losses
BlackRock has filed for a Bitcoin ETF that caps how much investors can gain in exchange for cushioning a portion of potential losses, a structure that trades Bi...
